Skip to content

Impact of Probiotic Preparation VSL#3 on Infants Colics

Impact of VSL#3 on Infants Colics as Assessed by Average Crying Time

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01869426
Enrollment
62
Registered
2013-06-05
Start date
2013-06-30
Completion date
2015-10-31
Last updated
2015-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infant Colics

Keywords

colics

Brief summary

Infantile colic is one of the most commonly reported medical problems within the first three months of life causing appreciable distress for both parents and pediatricians. It appears that multiple independent origins might be involved: amongst them infant's difficult temperament, inadequate mother-infant communication or maternal anxiety, transient lactase deficiency, exposure to cow's milk, abnormal gastrointestinal function, maternal smoking during pregnancy or after delivery. Consequently, various treatment approaches have been tried to alleviate this condition. Recent studies have suggested that changes of intestinal microflora of a newborn may play an important role in pathogenesis of infantile colic. Therefore, dietary supplementation with probiotics has been proposed for the improvement of this condition.

Detailed description

Aim of the study is to evaluate the improvement of colics symptoms by the oral administration of VSL#3 and the difference in the daily average crying time (measured with parental diary) between end of treatment and baseline. In this study, 62 infants will be enrolled and will receive 10 drops per day of VSL#3 or Placebo according to randomization list. The study product will be supplied as a box containing the oil bottle and a powder stick. The product should be stored refrigerated. On the first day of supplementation, the mother will open the sachet, pour the contents into the bottle and shake vigorously. A dropper is provided to count the drops. The suspension must be shaken vigorously before every use. Compliance will be monitored by filling out a diary.

Interventions

DIETARY_SUPPLEMENTVSL#3 drops
DIETARY_SUPPLEMENTVSL#3 drops placebo

Sponsors

Policlinico Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
30 Days to 90 Days
Healthy volunteers
No

Inclusion criteria

* Infants aged between 30 and 90 days * Breast fed exclusively during length of trial * Diagnosis of infantile colic according to Wessel's criteria i.e paroxysmal fussing in infancy for more than three hours per day, at least three days per week but not treated previously for colics. * Debut of colic symptoms 6+/-1 days before randomization * Written informed consent from one or both parents * Stated availability and reliability throughout the study period.

Exclusion criteria

* Major chronic disease * Gastrointestinal disease * Administration of antibiotics the week before randomization * Administration of probiotics two weeks before randomization * Infants with GI malformation, cystic fibrosis, other genetic diseases * Participation in other clinical trials.

Design outcomes

Primary

MeasureTime frameDescription
Improvement of colics symptoms3 weeksimprovement of colics symptoms by the oral administration of probiotic VSL#3 drops

Secondary

MeasureTime frameDescription
Difference in the daily average crying time between end of treatment and baseline.3 weeksDifference in the daily average crying time, measured with parental diary, between end of treatment and baseline.

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026